MENU
+Compare
MRUS
Stock ticker: NASDAQ
AS OF
Jan 23 closing price
Price
$41.11
Change
+$0.48 (+1.18%)
Capitalization
2.81B

MRUS Merus NV Forecast, Technical & Fundamental Analysis

a developer of therapeutics for cancer treatment

Industry Biotechnology
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for MRUS with price predictions
Jan 08, 2025

MRUS in +2.64% Uptrend, growing for three consecutive days on January 03, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MRUS advanced for three days, in of 269 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where MRUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on January 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on MRUS as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRUS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.002) is normal, around the industry mean (15.198). P/E Ratio (0.000) is within average values for comparable stocks, (88.809). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.840). MRUS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (70.423) is also within normal values, averaging (264.909).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MRUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

MRUS is expected to report earnings to fall 34.48% to -95 cents per share on March 04

Merus NV MRUS Stock Earnings Reports
Q4'24
Est.
$-0.96
Q3'24
Missed
by $0.60
Q2'24
Missed
by $0.05
Q1'24
Beat
by $0.22
Q4'23
Missed
by $0.27
The last earnings report on October 31 showed earnings per share of -146 cents, missing the estimate of -86 cents. With 380.38K shares outstanding, the current market capitalization sits at 2.81B.
A.I. Advisor
published General Information

General Information

a developer of therapeutics for cancer treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
Uppsalalaan 17
Phone
+31 302538800
Employees
229
Web
https://www.merus.nl
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CMLFX57.380.53
+0.93%
American Funds American Mutual 529F
OAYGX34.070.25
+0.74%
Oakmark Global Advisor
CHAIX16.670.10
+0.60%
Chase Growth Institutional
OSMCX31.850.17
+0.54%
Invesco International Small-Mid Com C
PEMLX14.060.02
+0.14%
Putnam Emerging Markets Equity R

MRUS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, MRUS has been loosely correlated with CYTK. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if MRUS jumps, then CYTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRUS
1D Price
Change %
MRUS100%
+1.18%
CYTK - MRUS
35%
Loosely correlated
+2.22%
VCYT - MRUS
34%
Loosely correlated
+2.37%
IMTX - MRUS
33%
Loosely correlated
+2.20%
GOSS - MRUS
33%
Poorly correlated
-1.78%
AMRN - MRUS
32%
Poorly correlated
+16.17%
More